Ziltivekimab

Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis[1][2].

Product Specifications

CAS Number

[2226654-05-1]

Product Name Alternative

COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ziltivekimab.html

Purity

99.75

Solubility

10 mM in DMSO

Smiles

[Ziltivekimab]

Molecular Weight

(145.39 kDa)

References & Citations

[1]Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2 (2) :224-235.|[2]Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117 (11) :e138-e140.|[3]Gluba-Brzózka A, et al. Emerging Anti-Atherosclerotic Therapies. Int J Mol Sci. 2021 Nov 9;22 (22) :12109.